Kim Chi, MD, associate professor of medicine and chair of the GU Tumor Group, British Columbia Cancer Agency, Vancouver, BC, discusses the most current and promising agents to combat prostate cancer that are in Phase 3 trials, along with what he views as the most compelling data from ASCO 2012. Dr. Chi discusses OGX 427, an inhibitor of HSP 27, which he has been working with through a promising Phase 2 trial.